Sigrid Therapeutics, an innovative, consumer-focused health company, today presented the results of a consumer trial ahead of the launch of their clinically proven SiPore® technology for blood sugar control in prediabetics and type 2 diabetics.
Sigrid Therapeutics, a Swedish consumer-focused technology company in consumer health, announced today that an additional SEK 10.6 million has been added to the company to accelerate the commercialization of its portfolio of dietary supplements based on SiPore®.
Sigrid Therapeutics, a Swedish consumer healthcare technology company, today announced that it has appointed Mattias Ankerberg as Chairman of the Board.
Sigrid Therapeutics, an innovative, consumer-focused health company that has developed a new technology, SiPore ® against prediabetes and obesity, announces today that the company, after 10 years of research, is in the starting blocks to launch its new, clinically proven product SiPore21 ® .
Swedish healthtech startup Sigrid Therapeutics is on its way to preventing two of the world's biggest health challenges, type 2 diabetes and obesity, with its SiPore15® powder.
Sigrid Therapeutics, a technology company specializing in the prevention of type 2 diabetes and obesity, announced today that the company has been granted a patent by the United States Patent and Trademark Office (USPTO).
Sigrid Therapeutics (Sigrid) announced today that the results from the company’s STAR study have been selected for presentation at the American Diabetes Association’s 80th Scientific Sessions, June 12-16, 2020.
Sigrid Therapeutics announced today that the Company has been named by FierceMedTech as one of the 2019 “Fierce 15” companies, one of the most promising private medtech companies in the industry. This is the first time in its eight-year history that a Swedish company has been included on the list.
Sigrid Therapeutics reports significant blood sugar reduction and excellent safety profile in the STAR study with SiPore15, a groundbreaking medical device for prediabetes and untreated type 2 diabetes
Sigrid Therapeutics AB, an innovative technology company developing a new class of products to improve human health, including type 2 diabetes, today announces that it has closed a rights issue of SEK 15.5 million.
Sigrid Therapeutics AB, a biotechnology company developing a new class of therapies in metabolic diseases, today announces that all patients have completed treatment with SiPore15 in the STAR clinical trial.
The leading American life science magazine BioSpace has named Sana Alajmovic one of 10 young life science innovators under the age of 40 to watch in the future.
At Almi Invest's 10th anniversary on May 28 at Nalen in Stockholm, Sigrid's CEO and Co-Founder Sana Alajmovic won the jury and audience's favor in the Startup Pitch of the Year competition.
The leading international life science journal Genetic Engineering News (GEN) has selected Sana Alajmovic, CEO of Sigrid Therapeutics, to this year's highly prestigious Top 10 Under 40 list 2019.
Sigrid Therapeutics today announced the publication of a large study in mice in the peer-reviewed journal Nanomedicine. The study demonstrates enzyme-blocking effects of mesoporous silica particles (MSPs) administered into the intestine with effects on food efficiency and metabolic risk factors as a result.